University of Florida Shands Children’s Hospital

Gainesville, FL

Description

University of Florida Shands Children’s Hospital is ranked by U.S. News and World Report among the nation’s best, and our pediatric oncology program is the highest ranked program in Florida.  This recognition, combined with an overall mission to care for and support our patients and families, leads to advanced treatment with a personalized touch from our pediatric neuro-oncology team.

Our interdisciplinary clinical team includes pediatric experts from numerous departments throughout UF Health.  These include: neuro-oncology, neurosurgery, radiation oncology, neurology, neuroradiology, neuropathology, bone marrow transplant, anesthesiology, and neuropsychology.  The care of children at University of Florida Shands Children’s Hospital is aided greatly by the full range of pediatric services, including nursing, physical therapy, occupational therapy, speech therapy, social work, and child life.  The new UF Health Neuromedicine tower provides a welcoming clinic space for outpatient visits as well as intraoperative MRI.

The highly trained physicians and scientists at the Preston A. Wells Jr. Center for Brain Tumor Therapy take a patient-centered approach to care.  Because no two individuals respond in the same way to any treatment, the multidisciplinary team of specialists provides highly individualized diagnostics and treatment plans.  The ultimate goal is to provide the optimal patient experience.

Housing Information

For more information about housing at this site, please visit the UF Health website.

Contact information

 

Mailing address:

 Dr. Sri Gururangan
 PO Box 100265
 Gainesville, FL 32610

Phone: 352-273-9000

Team

Principal Investigator
Pediatric Neuro-oncologist
Sridharan Gururangan, FRCP (Edin.), received his medical degree in 1981 from the University of Madras Chennai, India, proceeded to train in pediatrics in the United Kingdom and eventually became a Member of the Royal College of Physicians, U.K, in 1988. He was subsequently elected to fellowship from the Royal College of Physicians in Edinburgh, U.K. in 2015. He became interested in treating children with cancer during his pediatric training in the U.K. and completed a leukemia research fellowship in Manchester, England. Dr. Gururangan moved to the United States in 1991 to pursue his interest in pediatric oncology at St. Jude Children’s Hospital in Memphis, Tenn. and the Memorial Sloan Kettering Cancer Center in New York where he completed his fellowship in pediatric hematology-oncology in 1999. Dr. Gururangan moved to North Carolina to practice at Duke University Medical Center as the director of pediatric neuro-oncology at the Preston Robert Tisch Brain Tumor Center. For 17 years, he treated more than 1,200 children with brain tumors there and led several innovative clinical trials through his interaction with other investigators nationwide. Dr. Gururangan joined the UF faculty as an endowed professor in the UF department of neurosurgery in 2016. He also holds a joint appointment in the UF department of pediatrics. He is board certified in pediatric hematology-oncology and neuro-oncology. He is passionate about treating children with brain cancer and has been a resource and source of support for countless patients and family members. Dr. Gururangan’s research interests are in developing new strategies for treatment of children with brain tumors with a special focus in the development of phase I and II trials of new drugs, including novel chemotherapy agents, small molecule inhibitors targeting receptor tyrosine kinases, anti-angiogenesis inhibitors, pharmacologic strategies that lead to reversal of drug resistance to alkylating agents, immunotherapy approaches to the treatment of recurrent medulloblastoma, and oncolytic viral therapy for neoplastic meningitis. His clinical research has led to more than 100 peer-reviewed publications in prestigious journals, five book chapters and more than 115 abstracts presented at various national and international scientific meetings. Dr. Gururangan has earned several awards for his work with pediatric cancer patients, including the Excellence in Pediatric Clinical Research Award from the Society for Neuro-Oncology and two Shining Star Awards from the Make-A-Wish Foundation. Dr. Gururangan is a member of the Pediatric Brain Tumor Consortium and the Children’s Oncology Group.
Co-Principal Investigator
Neuro-oncologist
Duane A. Mitchell, M.D., Ph.D. is Co-Director of the Preston A. Wells Jr. Center for Brain Tumor Therapy and Director of the UF Brain Tumor Immunotherapy Program. He is the Phyllis Kottler Friedman Professor in the Department of Neurosurgery and the State of Florida Endowed Cancer Research Chair at the University of Florida College of Medicine. In 2013, Dr. Mitchell joined the University of Florida faculty and leads a comprehensive brain tumor program focused on translational research. He has considerable clinical and translational research experience having served as principal investigator on seven first-in-human protocols through FDA-approved clinical trials. The goal of these trials is to see improvements in patient outcomes using novel approaches that stimulate immune responses against malignant brain tumor cells in combination with current standard treatments. Dr. Mitchell’s research team will expand upon early successes observed in these personalized cancer treatment approaches, and offer unique clinical options at UF for adult and pediatric patients diagnosed with malignant brain tumors. Dr. Mitchell currently serves as a chartered member of the NIH study section on Cancer Immunopathology and Immunotherapy, Chair of the NCI Pediatric Brain Tumor Consortium Immunotherapy Committee, member of the NCI Brain Malignancy Steering Committee Mitchell commencement address to UF doctural graduatesImmunotherapy Working Group, and as gubernatorial appointee to the Florida Center for Brain Tumor Research Scientific Advisory Council. He also serves as Program Leader for the UF Health Cancer Center, Cancer Therapeutics and Immuno-Oncology (CTI) research program. Dr. Mitchell has more than 40 refereed journal publications, 15 textbook chapters and scientific reviews, and is inventor on five United States patents on findings from his oncological research. He has been invited to serve on several scientific advisory boards and to speak on neuro-oncology in local, national, and international venues. His work is supported by the Department of Defense, the National Cancer Institute, the National Institute of Neurologic Diseases and Stroke, and several private funding agencies.
Pediatric Neurosurgeon
Pediatric Neurosurgeon